The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1). 

Original Source

Despite evidence that taking powerful anti-HIV drugs can help protect uninfected partners from contracting the virus that causes AIDS, the therapy is far from becoming routinely prescribed, scienti

Two new Ebola vaccine trials began on Wednesday with volunteers in Britain, France and Senegal getting "prime-boost" immunisations developed by Bavarian Nordic, GlaxoSmithKline and Johnson & Jo

Researchers at the University of Texas Medical Branch (UTMB), Galveston have discovered an inhalable vaccine that can protect rhesus macaque monkeys against severe illness and death when they were

A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.

Clinical trials in India have again come under the regulatory scanner after the World Health Organisation (WHO) pointed out “critical“ lapses in trials of HIV drugs being conducted by a Chennaibase

Scientists may have managed to unravel the elusive structure of the HIV protein.

The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose.

A staggering range of commonly used chemicals ­ from insecticides to plastic additives to some common medications ­used even in very low quantities are likely to cause cancer.

Zimbabweans may soon be immunised against HIV transmission if trials for a vaccine to prevent the spread of the deadly virus expected to start in the near future are successful.

Pages